Benzinga | Apr 19, 2021 08:39AM EDT

Veracyte Announces Data For Pulmonology Portfolio To Be Presented At American Thoracic Society 2021 International Conference

- New data support role of Percepta Genomic Atlas in genomic profiling for lung cancer patients --

- Study suggests Envisia classifier can be successfully enabled on nCounter Analysis System -

Veracyte, Inc. (NASDAQ:VCYT) announced today that new data demonstrating the clinical capability of the Percepta(r) Genomic Atlas for informing lung cancer treatment decisions, as well as the technical feasibility of enabling the company's Envisia(r) Genomic Classifier on the nCounter Analysis System, will be presented at the American Thoracic Society (ATS) 2021 International Conference. Multiple posters reinforcing the Envisia classifier's diagnostic performance will also be presented at the meeting, which will be held virtually May 14-19, 2021.

"The data being presented at ATS suggest that the Percepta Genomic Atlas can provide information that will accelerate appropriate treatment for patients following a lung cancer diagnosis and, importantly, that the test provides this information regardless of disease stage," said Bonnie Anderson, Veracyte's chairman and chief executive officer. "We're also very excited about the new data demonstrating that we can successfully enable the Envisia classifier on the nCounter system, maintaining the test's clinical performance while enabling access for patients globally through local labs."

The Percepta Genomic Atlas provides comprehensive genomic profiling information on cancerous lung nodules, utilizing small samples from the same biopsy used for diagnosis. Data to be shared at ATS show that the in-development test accurately detects known gene variants in lung cancer using bronchoscopy samples, potentially enabling earlier and more appropriate treatment with currently available and in-development targeted therapies.

The Envisia Genomic Classifier is a genomic test that detects a genomic pattern of usual interstitial pneumonia (UIP) to improve interstitial lung disease (ILD) diagnostic and prognostic confidence. The classifier is performed in Veracyte's U.S.-based CLIA laboratory. In December 2019, Veracyte acquired the exclusive global diagnostics rights to the nCounter Analysis System, a CE-marked and FDA-cleared decentralized molecular testing platform. The company plans to make the Envisia classifier available on the nCounter platform in international markets by the end of this year.

Following are details of the Percepta Genomic Atlas and Envisia classifier posters accepted for presentation at ATS. These posters will be available to meeting registrants on demand beginning May 14 through July 2, 2021:

Identification of Driver Mutations in Transbronchial Needle AspiratesTitle: of Suspicious Lung Nodules Concurrent with Diagnostic Bronchoscopy, Abstract #A4825

First Joshua Babiarz, Ph.D., VeracyteAuthor:



Title: Envisia Genomic Classifier Demonstrates Consistent Performance Across Gender, Age Group, and Smoking Status. Abstract #A1839

First Luca Richeldi, M.D., Ph.D., Universita' Cattolica del Sacro Cuore,Author: Rome, Italy



Title: Envisia Genomic Classifier Helps Improve Multidisciplinary Diagnoses of Complex Interstitial Lung Diseases, Abstract #A1877

First Lisa H. Lancaster, M.D., Vanderbilt University Medical CenterAuthor:



Title: Cryobiopsy and Genomic Classifier (Envisia) in the Diagnosis of Usual Interstitial Pneumonia, Abstract #A4236

First R. Ronaghi, M.D., University of California, Los AngelesAuthor:



Title: Role of the Envisia Genomic Classifier in Establishing a Diagnosis of Idiopathic Pulmonary Fibrosis, Abstract #1837

First M. Abdalla, M.D., Pulmonary and Critical Care Medicine, Medical CollegeAuthor: of Wisconsin



Title: Bridging the Envisia Genomic Classifier to the nCounter Platform: A Proof-of-Concept Study, Abstract #A4352

First Huimin Jiang, Ph.D., VeracyteAuthor: